Swiss biotech company Roivant Sciences to go public via $7.3B SPAC deal
Roivant Sciences, a biopharmaceutical & healthcare technology company, has announced that it is going public via SPAC. The biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp. (Nasdaq: MAAC),…